OIA Signs Collaboration and Commercial Agreement With the NHS

Share this
Share on facebook
Share on twitter
Share on print
Share on email

We are thrilled to announce that Oxford Immune Algorithmics signed last week a collaboration and commercial agreement with the National Health Service in the UK to serve and continue co-developing Algocyte® in Addenbrooke’s Hospital at the Cambridge University Hospitals NHS Foundation Trust, one of the most important hospitals in the UK.

Algocyte® will be deployed at the Department of Paediatric Haematology, Oncology and Palliative Care to help paediatric cancer patients to get supportive monitoring while preventing them to visit the hospital where they are exposed to greater risk of infection due to COVID-19.

​We want to thank partners, collaborators and investors that made this possible believing in us and supporting our project to help clinicians and these vulnerable patients.

Sign up to receive more information